Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
Pilot Study: Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a rapidly growing epidemic worldwide and is an increasingly important etiology of chronic liver disease and hepatocellular carcinoma. NAFLD affects approximately 90 million people in the United States (US) amounting to an annual cost of $100 billion yearly. It is projected to become the leading cause of liver transplantation in the US by 2030 and is associated with significant morbidity and mortality. NAFLD is a spectrum of liver diseases, ranging from simple steatosis (nonalcoholic fatty liver, NAFL) to hepatic steatosis associated with inflammation (nonalcoholic steatohepatitis, NASH), which can be associated with liver scarring (hepatic fibrosis) and cirrhosis. There are limited therapeutic options that have been shown to effectively reduce or reverse the progression of disease.
Lifestyle modification is the backbone of therapy, but difficult to achieve. A modest amount of weight loss of approximately 3% can reduce liver steatosis and a 10% weight loss can reduce the NASH and improve liver fibrosis. The American Association of the Study of Liver Diseases (AASLD) guidelines state that "a combination of a hypocaloric diet (daily reduction by 500-1000 kcal) and moderate intensity exercise is the best likelihood of sustaining weight loss over time." There are several barriers to adopting a healthy lifestyle involving both patient and physician limitations. The aim of this study is to engage patients in a lifestyle intervention program that has already been shown to be successful in achieving weight loss goals and adopting healthier lifestyle patterns.
The CDC Diabetes Prevention Program, (DPP) was a large (n=3,234) multicenter study aimed to evaluate the effect of lifestyle intervention or treatment with metformin on the incidence of type 2 diabetes (T2DM). Lifestyle intervention reduced the incidence of T2DM by 58% (95% CI, 48-66%) and metformin reduced the incidence by 31% (95% CI, 17-43%) as compared to placebo. To prevent one case of diabetes over three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin. The CDC DPP program has been adapted and tested in the multiple different community and state-wide programs including the YMCA, WorkWellNYC and NYS DPP. In these real-world models, the life style intervention program has been delivered in a group-based format by DPP lifestyle coaches. These programs have been successful like that of the randomized trial and improvements were sustainable at 6 and 12 month follow up after completion of the program. The program is now available and reimbursable through Medicare (Medicare Diabetes Prevention Program).
In this pilot study, the researchers will enroll 20 patients with NAFLD in an adapted DPP program and follow study participants for 1 year. The rationale for the proposed research is to apply the DPP to NAFLD because of the close relationship with Diabetes and determine the real-world outcome of the DPP program on weight loss in patients with NAFLD. If the researchers illustrate that weight loss can be achieved and is sustainable in patients with NAFLD enrolled in lifestyle intervention programs, the researchers can develop innovative approaches to deliver such a program nationwide in a cost-effective and sustainable manner.
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
New York
-
New York、New York、美国、10003
- Mount Sinai Union Square
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- diagnosis of NAFLD, defined by the presence of hepatic steatosis with vibration controlled transient elastography (VCTE) controlled attenuation parameter (CAP) measurement over 240dB/m, or liver biopsy showing macrovesicular steatosis in ≥ 5% of hepatocytes.
- patients were 18 years and older,
- fluent in English (the program could only be conducted in English by the DPP-certified coach),
- able to meet program scheduling requirements, and able to participate in physical activity.
Exclusion Criteria:
- additional causes of liver disease such as viral hepatitis, biliary obstruction, hepatocellular carcinoma, Wilson's disease, Budd Chiari Syndrome, autoimmune hepatitis, alcoholic liver disease or alcohol use (>20g/day women, >30g/day men),
- aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values >300 U/L,
- using steatogenic medications (amiodarone, methotrexate, tamoxifen, and corticosteroids),
- pregnant,
- a history of liver transplantation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Treatment Arm
Patients enrolled in 1 year program
|
The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes.
Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of participants in the program at the end of the study
大体时间:12 months
|
Retention defined as number of patients in the program at the end of the study
|
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change in Weight
大体时间:baseline and 12 months
|
Change in Weight at 12 months as compared to baseline
|
baseline and 12 months
|
Hepatic steatosis via Fibroscan
大体时间:Baseline
|
Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter.
|
Baseline
|
Hepatic steatosis via Fibroscan
大体时间:6 months
|
Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter .
|
6 months
|
Hepatic steatosis via Fibroscan
大体时间:12 months
|
Changes in hepatic steatosis measured with fibroscan using the controlled attenuated parameter.
|
12 months
|
Glycosylated A1C
大体时间:Baseline
|
Glycosylated A1C in assessing metabolic comorbidity
|
Baseline
|
Glycosylated A1C
大体时间:6 months
|
Glycosylated A1C in assessing metabolic comorbidity
|
6 months
|
Glycosylated A1C
大体时间:12 months
|
Glycosylated A1C in assessing metabolic comorbidity
|
12 months
|
Lipid levels
大体时间:Baseline
|
Lipid levels in assessing metabolic comorbidity
|
Baseline
|
Lipid levels
大体时间:6 months
|
Lipid levels in assessing metabolic comorbidity
|
6 months
|
Lipid levels
大体时间:12 months
|
Lipid levels in assessing metabolic comorbidity
|
12 months
|
Liver enzymes levels
大体时间:Baseline
|
Liver enzymes levels for ALT, AST, and ALP
|
Baseline
|
Liver enzymes levels
大体时间:6 months
|
Liver enzymes levels for ALT, AST, and ALP
|
6 months
|
Liver enzymes levels
大体时间:12 months
|
Liver enzymes levels for ALT, AST, and ALP
|
12 months
|
Bilirubin level
大体时间:Baseline
|
Liver enzyme level for Bilirubin
|
Baseline
|
Bilirubin level
大体时间:6 months
|
Liver enzyme level for Bilirubin
|
6 months
|
Bilirubin level
大体时间:12 months
|
Liver enzyme level for Bilirubin
|
12 months
|
合作者和调查者
调查人员
- 首席研究员:Amreen Dinani、Icahn School of Medicine, Division of Liver Diseases
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Diabetes Prevention Program的临床试验
-
UConn HealthUniversity of Texas at Austin; Oregon Social Learning Center邀请报名
-
University of ManchesterNational Secretariat of Science, Technology and Innovation in Panama (SENACYT)完全的
-
University of Maryland, BaltimoreNational Institute on Aging (NIA)完全的
-
The University of Hong KongSydney Children's Hospitals Network; SAHK招聘中
-
Helse Nord-Trøndelag HFNorwegian University of Science and Technology完全的